Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024...
PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre...
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area Webinar being held...
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie Tenue d’un...
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" PHAXIAM Presented its...
PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » PHAXIAM a...
PHAXIAM Reports Third-Quarter 2024 Financial Information Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical...
PHAXIAM publie l’information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie de 5,7 M€ au 30 septembre...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Information mensuelle...
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Monthly information related...
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. GLORIA, the world's 1st phase II phage therapy study in...
PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis GLORIA, 1ère étude mondiale...
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024 Listing market: Euronext...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024 Place de cotation :...
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study A Phase 2 study sponsored by Assistance Publique –...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지